quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:05:00·708d
PRRelease
enGene Therapeutics Inc. logo
NewAmsterdam Pharma Company N.V. logo
Nkarta Inc. logo
+2

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

ENGN· enGene Therapeutics Inc.NAMS· NewAmsterdam Pharma Company N.V.NKTX· Nkarta Inc.PCRX· Pacira BioSciences Inc.VECT· VectivBio Holding AG
Health Care
Original source

Companies

  • ENGN
    enGene Therapeutics Inc.
    Health Care
  • NAMS
    NewAmsterdam Pharma Company N.V.
    Health Care
  • NKTX
    Nkarta Inc.
    Health Care
  • PCRX
    Pacira BioSciences Inc.
    Health Care
  • VECT
    VectivBio Holding AG
    Health Care

Recent analyst ratings

  • Apr 13ENGNUpdateWBB Securities$21.50
  • Mar 18NAMSUpdateTruist$57.00
  • Jan 30ENGNUpdateJefferies$28.00
  • Dec 9PCRXUpdateBarclays$27.00
  • Nov 17PCRXUpdateH.C. Wainwright-
  • Nov 11ENGNUpdateRaymond James$27.00

Related

  • SEC18h
    SEC Form DEFA14A filed by Nkarta Inc.
  • SEC18h
    SEC Form DEF 14A filed by Nkarta Inc.
  • INSIDER1d
    SEC Form 4 filed by Cross Shawn
  • SEC4d
    SEC Form PRE 14A filed by NewAmsterdam Pharma Company N.V.
  • SEC6d
    SEC Form PREC14A filed by Pacira BioSciences Inc.
  • PR8d
    Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026
  • PR8d
    Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
  • ANALYST11d
    WBB Securities initiated coverage on enGene Therapeutics with a new price target
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022